The MGMT methylation pattern has the main role in the management of patients affected by GBM: MGMT promoter hypermethylation causes the abolishment of MGMT protein expression and, as a consequence, favors a better response to temozolomide (TMZ), leading to a significant improvement in patient outcomes [3,7,8]. This evidence concerns the gene MGMT and glioblastoma.